Table 3.
Distribution of major anticholinergic adverse events in each group over 52 weeks.
| Variable, n (%) | Imidafenacin | Solifenacin | P-value |
|---|---|---|---|
| N (safety population) | 21 | 20 | |
| Dry mouth | 15 (71.4%) | 18 (90.0%) | 0.2379b |
| Mild | 8 (38.1%) | 4 (20.0%) | |
| Moderate | 7 (33.3%) | 10 (50.0%) | 0.0092a |
| Severe | 0 (0%) | 4 (20.0%) | |
| Constipation | 3 (14.3%) | 13 (65.0%) | 0.0013b |
| Blurred vision | 2 (9.5 %) | 7 (35.0%) | 0.0670b |
The severity of dry mouth was evaluated on a 3-point scale: mild, barely noticeable; moderate, tolerable after drinking water; severe, intolerable after drinking water, leading to discontinuation of the investigational drug;
a: Mann-Whitney U test, b: Fisher exact test, two-sided.